Preliminary Validation of a Multispectral Image Analysis Application for Confirmation of Isolated Tumor Cells in Axillary Lymph Nodes from Breast Cancer.

Slides:



Advertisements
Similar presentations
BREAST SENTINEL NODE LOCALISATION & BIOPSY
Advertisements

Rev B 09/2012 ChromoPlex 1 Dual Detection Multiply Your Capabilities Leica ChromoPlex TM 1 Dual Detection for Leica BOND.
Toward a molecular intra-operative diagnosis of SLN invasion R Garrel 1, V Burcia 1, J Solassol 2, V Costes 3, E Barbotte 4, D DeVerbizier 5, C Cartier.
Use of intra-operative frozen section in surgery for potential early stage ovarian malignancy September 2011 Dr Paul Cross Consultant Cellular Pathologist.
The Laval University (Québec) virtual slide telepathology project; A structured patient-oriented network involving 21 sites Bernard Têtu MD, Medical director.
Wednesday August 16, 2006 APIII 2006 Vancouver Breakout Session A2 Whole Slide Image System Implementation Jeffrey Fine MD University of Pittsburgh.
Resolution.
Sentinel Lymph Node procedure Intraoperative Examination Belgian Breast Meeting 14/10/2006 Daniel Faverly MD Pathology Laboratory CMP-LabPatho Centre Communautaire.
Frank P. Dawry LYMPHOSCINTIGRAPHY Sentinel node localization in Melanoma.
Malignant Adenomyoepithelioma of the Breast with Lymph Node Metastasis
S ENTINEL L YMPH N ODE M ICROMETASTASIS IN B REAST C ANCER Anthony Fong Yan Chai Hospital.
Magee-Womens Hospital of UPMC
Discordance in Hormone Receptor and HER2 Status in Breast Cancer during Tumor Progression Lindstrom LS et al. Proc SABCS 2010;Abstract S3-5.
Clinical Utility of Combidex in Various Cancers
Predictors of HER2 FISH amplification in immunohistochemistry score 2+ infiltrating breast cancer: a single institution analysis Maria Vittoria Dieci 1,
Breast Cancers With Brain Metastases are More Likely to be Estrogen Receptor Negative, Express the Basal Cytokeratin CK5/6, and Overexpress HER2 or EGFR.
Round-Robin Review of HER2 Testing in the Context of Adjuvant Therapy for Breast Cancer (NCCTG N9831/BCIRG006/BCIRG005) 1 Concordance of HER2 Central Assessment.
Quantitative Image Analysis of HER2 Immunohistochemistry Compared with Manual Pathologist Analysis in Breast Cancer A Pilot Study Keith J.Kaplan, MD Geoffrey.
Moving Toward Personalized Treatment for Gastric Cancer: Role of HER2 Testing Frédérique Penault-Llorca, MD, PhD Professor of Pathology Centre Jean Perrin.
Tuthill et al, Henry Ford Health Systen Bar Code Specified Surgical Pathology Workflow Joy J Mammen MD; Richard Zarbo MD; Adrian Ormsby MD; J. Mark Tuthill.
High Volume Slide Scanning Architecture and Applications
Isolation of Rare Circulating Tumor Cells Sunitha Nagrath et al. Presentation.
© Copyright 2003 Cardinal Health, Inc. or one of its subsidiaries. All rights reserved. PET in Breast Cancer Early detection of disease Precise Staging.
AJCC Staging Moments AJCC TNM Staging 7th Edition Breast Case #2 Contributors: Stephen B. Edge, MD Roswell Park Cancer Institute, Buffalo, New York David.
Sentinel Node Biopsy : the way forward Hemant Singhal MS FRCSEd FRCS(Gen) FRCSC Consultant Surgeon Northwick Park & St Marks Hospital Senior Lecturer,
Real world HER2 testing - are they reliable? Result of the planned analysis of the initial 104 cases enrolled by IHC in NSABP B-31 Soonmyung Paik, MD Division.
Background Sentinel lymph node biopsy has been recently introduced in the clinical setting because it is highly accurate in predicting the lymph node status.
EVALUATION OF LYMPH NODES & PATHOLOGIC EXAMINATION FOR BREAST CASES Tonya Brandenburg, MHA, CTR Kentucky Cancer Registry.
1 CAP Audio Conference on the CMS 2009 Physician Quality Reporting Initiative Jonathan Myles, MD, FCAP College of American Pathologists December 17, 2008.
11th Biennial Meeting of the International Gynecologic Cancer Society 11th Biennial Meeting of the International Gynecologic Cancer Society Semih Gorgulu,
Clinical Trials Evaluating the Role of Sentinel Node Resection in Patients with Early-Stage Breast Cancer Krag DN et al. Proc ASCO 2010;Abstract LBA505.
INTRAOPERATORY ASSESSMENT OF SENTINEL NODE IN BREAST CANCER PERFORMING ONE STEP NUCLEIC ACID AMPLIFICATION (OSNA) ASSAY ON THE WHOLE LYMPH NODE Sapino.
Changes in Breast Cancer Reports After Second Opinion Dr. Vicente Marco Department of Pathology Hospital Quiron Barcelona. Spain.
GENIE: Automated Feature Extraction for Pathology Applications Neal R. Harvey Kim Edlund Los Alamos National Laboratory
Diagnostic Challenge Pathology for Neurosurgery & Neurology Residents Department of Pathology University of Oklahoma Health Sciences Center, Oklahoma City,
Pathology Reports Nicole Draper, MD.
What is an image? What is an image and which image bands are “best” for visual interpretation?
Prostate Cancer CAD Michael Feldman, MD, PhD Assistant Professor Pathology University Pennsylvania.
Grading And Staging Grading is based on the microscopic features of the cells which compose a tumor and is specific for the tumor type. Staging is based.
SLNB The RUH experience A 2014 Audit Dr M Stoddart, Dr S Cole, Mr J Horsnell and Mr R Sutton Royal United Hospital, Bath.
Breast Anatomic sites and subsites of the breast. Compton, C.C., Byrd, D.R., et al., Editors. AJCC CancerStaging Atlas, 2nd Edition. New York: Springer,
“Isolation of rare circulating tumour cells in cancer patients by microchip technology” Nagrath et al. Nature 2007 Peter Bojo.
Introduction:. introduction Thera are 5 multigene expression based prognostic tests for breast cancer offered as reference lab test: Mammaprint,MapQuant,DX,OncotypeDX,PAM50.
12 th European Congress on Digital Pathology previously European Congress on Telepathology and international Congress on Virtual Microscopy College des.
Factors affecting failed localisation and false-negative rates of ex-vivo sentinel lymph node mapping in colorectal cancer. Sommariva A, Gnocato B, Tollot.
CLINICAL ASPECT OF GRADING AND STAGING Hanggoro Tri Rinonce, MD, PhD Department of Anatomical Pathology Faculty of Medicine, Gadjah Mada University.
Validation and Interpretation in Cellular Pathology
Institute for Pathology, University Hospital Erlangen
CORRELATION OF PHYSICAL EVALUATION AND MRI OF CERVICAL LYMPH NODE WITH HISTOPATHOLOGICAL FINDINGS IN ORAL SQUAMOUS CELL CARCINOMA: AN AMBIDIRECTIONAL STUDY.
CAMELYON17: Moving the challenge to patient level
HER2 and estrogen receptor status drive decisions regarding the use of neoadjuvant chemotherapy Neil Love, MD1, Kimberly L Blackwell, MD2, Eleftherios.
Erica V. Bloomquist, MD Heather Wright, MD
Figure 1 Comparison of tumor size at time of excision between axillary node-negative, axillary node-positive, and distant metastasis subgroups of basal-like.
Digital Pathology Early Adoption Douglas J
徐慧萍1 羅竹君1,2 郭耀隆1 李國鼎1 國立成功大學醫學院附設醫院外科部1 國立成功大學醫學院臨床醫學研究所2
Neoadjuvant Therapy in HER2-Positive Breast Cancer
Optimizing Outcomes in the Management of GIST
A Comparative Performance Analysis of Multispectral and RGB Imaging on HER2 Status Evaluation for the Prediction of Breast Cancer Prognosis  Wenlou Liu,
Management of Skull Base Metastases
What Can Immunology Tells Us About Breast Cancer?
New Views into the Genetic Landscape of Metastatic Breast Cancer
Characterizing the Histologic Morphology of Liver Cancer: Creating a Formalin Fixed Paraffin Embedded Tissue Repository Tamar Taddei, MD.
Cancer 101: A Cancer Education and Training Program for [Target Population] Date Location Presented by: Presenter 1 Presenter 2 1.
The Prognostic Importance of Immunohistochemically Detected Node Metastases in Resected Esophageal Adenocarcinoma  Tara A. Waterman, BA, Jeffrey A. Hagen,
IL6 mRNA is not detected in metastatic prostate cancer cells.
AXL is not expressed in human prostate tumors.
BAF57 is highly expressed in human prostate cancer specimens.
Evidence Based Diagnosis
Concordance between liquid versus tissue biopsies.
Presentation transcript:

Preliminary Validation of a Multispectral Image Analysis Application for Confirmation of Isolated Tumor Cells in Axillary Lymph Nodes from Breast Cancer Patients Jeffrey Fine MD, K McManus, A Luketich, D Dabbs MD University of Pittsburgh

Objectives Background – Hard to Stain Breast Cancer Metastases – Multispectral Image Analysis Clinical Application & Validation Path Forward

Sentinel Lymph Node Biopsy (Breast Cancer) Surgeon identifies axillary nodes most likely to contain metastatic disease If negative, no further biopsy needed – Low probability of unsampled disease If positive…it depends on how positive

Multispectral Image Analysis (MSI)

Image based on spectral information instead of color Each pixel has a spectrum instead of a color This data permits “demixing” the ‘colors’

Light Sensitivity Wavelength RGB

Light Sensitivity Wavelength 7 Bands

How to Stain Very Small Foci Try a traditional stain (it might work) Destain the H&E and Immunostain that slide Immunostain the H&E directly then use MSI to demix the colors and create both H&E and Immunostain images

Application Perform Cytokeratin Immunostain onto H&E – “multiplex” H&E and IHC Use MSI to produce FALSE COLOR IMAGES – Pseudo H&E – Pseudo IHC

Details Macrometastases for initial validation – Only 5 cases to start Immunostaining – AE1/AE3 antibody (Dako) – Benchmark XT (Ventana) MSI – Nuance System (CRi)

Suspense Spared Validated relative to traditional stains – Positive and negative controls Stain not as brilliant but visible Stain process bleached H&E—re-staining required (H, E, and DAB staining required to create good false color images)

Workflow Pathologist orders an MSI protocol, gives slide to IHC lab AE 1/3 stain performed on H&E (details omitted) Slide given to Pathologist (for now) for MSI

Results False color H&E and AE1/3 images returned to pathologist …Slide returned as well

Why… …is the slide returned? – Easily verifiable by eye—no need for blind trust …lymph nodes? – Uncommon (not rare) frustrating situation …bother?

Why do MSI in these cases? Introduction of MSI technology into semi- routine surgical pathology workflow Demonstration of technology to other pathologists Development of MSI workflow for other applications

Challenges Original H&E still “destroyed” – Whole Slide Image archival Limited field of view—cannot MSI the entire slide (foci must be marked as with FISH slides) Demixing is very far from perfect – IHC pretty good but digital H&E is in progress

Presentation Demixing limitations – Crosstalk prevents creation of higher quality false color H&E Presentation – Optimal false color combinations need tweaking

Next Steps Longer semi-validation phase – Continue attempting regular IHC on these cases – Return original slide to pathologist for validation Publicize availability to increase volume – First me; then select others; then everybody

Next Applications Breast—microinvasion (myoepithelial markers) Prostate biopsies – small foci Greater “automation” – performance by technical staff

Concluding Thoughts Available NOW (MSI today) – Imperfect but it validates – Leads directly to other similar applications This can drive improvements – General image analysis workflow (inc delegation) – Better algorithms – Experience (currently more of an art)